Legal & General Group
MPLT

Legal & General Group’s MapLight Therapeutics MPLT Stock Holding History

Legal & General Group’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.7K Buy
1,805
+156
+9% +$2.79K ﹤0.01% 2760
2025
Q4 		$29K Buy
+1,649
New +$27.6K ﹤0.01% 2888

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Legal & General Group's MPLT Position: Q1 2026 in Review

Legal & General Group increased its MapLight Therapeutics (MPLT) stake by 9.5% in Q1 2026, buying an estimated $2.79K and bringing the position to 1,805 shares worth $36.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2760.

Legal & General Group first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Legal & General Group held 1,805 shares of MapLight Therapeutics worth $36.7K as of Q1 2026.
  • Legal & General Group bought 156 MapLight Therapeutics shares in Q1 2026, an estimated $2.79K.
  • MapLight Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2760 holding.
  • Legal & General Group first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.